Home/Pipeline/seRNA 005

seRNA 005

Autoimmune Diseases

ResearchActive

Key Facts

Indication

Autoimmune Diseases

Phase

Research

Status

Active

Company

SRTD biotech

About SRTD biotech

SRTD Biotech is a private, preclinical-stage biotech developing a proprietary 'RNA pro-drug' platform termed seRNA (selectively expressed RNA). The technology merges RNA interference for cell-specific targeting with mRNA for effector molecule expression, delivered via proprietary lipid nanoparticles (fLNPs). The company's initial pipeline focuses on oncology (HCC, glioblastoma, lung cancer), with plans to expand into viral and autoimmune diseases, aiming to overcome the off-target side effects common to many existing therapies.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases Viral Diseases

Other Autoimmune Diseases Drugs

Drug	Company	Phase	Status
Humira (Adalimumab) Biosimilar	NeuClone	Early Preclinical	Active
HBM7020	Harbour BioMed	Discovery	Out-Licensed
R2006	Harbour BioMed	Discovery	Active (Global)
R7027	Harbour BioMed	Discovery	Active (Global)
ImmCelz™ Platform	Creative Medical Technology Holdings	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Gavocabtagene autoleucel	astellas	Phase 1/2	Active
TYK-101	TYK Medicines	Phase 1	Active
HCB206	HanchorBio	Preclinical	Active
miR-124 Activator	Formation Bio	Phase 2	Active
Autologous Cell Therapy Collaboration	Lupagen	Preclinical	Active
Autoimmune Diagnostics Leadership Initiative	Vibrant America Clinical Laboratory	Commercial	Active